



# The TIMI Trials

## **TIMI 9 Registry:**

### **OBJECTIVES:**

**To assess management strategies and the outcomes of patients presenting with ST elevation myocardial infarction in the current era of aggressive reperfusion strategies.**

**To assess the outcomes of patients presenting with ST elevation myocardial infarction who are ineligible for fibrinolytic therapy.**

1. Cannon CP, Bahit MC, Haugland JM, et al. Underutilization of evidence-based medications in acute ST elevation myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 9 Registry. *Crit Path Cardiol* 2002;1:44-52.
2. Henry TD, Haugland JM, Berger C, Gleason R, Antman EM, Sharkey SW, for the TIMI 9 Registry Investigators. Is "door to needle" time, unadjusted for severity of illness a suitable measure of mortality risk in patients with acute myocardial infarction? *Circulation* 1995;92(Suppl. 1):1-775-776.
3. Steingart RM, McKendall GR, Cannon CP, Macina G, Bilodeau S, Pier M, Kikel M, McCabe CH, Braunwald E, for the TIMI 9 Registry Investigators and Coordinators. Resolution of chest pain and ST segment elevation in acute myocardial infarction and the decision to give reperfusion therapy: Results from the TIMI 9 Registry. *Circulation* 1995;92(Suppl. 1):1-205-206.
4. Paul S, McCabe CH, Antman EM. Risk stratification for acute myocardial infarction in the emergency department. *Circulation* 1997;96:1-182.
5. Bahit MC, Cannon CP, Antman EM, et al. Critical pathway for acute ST-segment elevation myocardial infarction: evaluation of the potential impact in the TIMI 9 Registry. *Crit Pathways Med* 2002;1:44-52.
6. Bahit MC, Cannon CP, Antman EM, Gibson CM, Murphy S, McCabe CH, Braunwald E. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 trial and TIMI 9 registry. *Am Heart J* 2002 2003;145:109-117.